Association between hospital-diagnosed tinnitus and suicide: A nationwide Danish longitudinal study
Increases HDL (good cholesterol)
GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
Goal: to summarize the mechanisms and clinical implications
Regulation of Appetite and Metabolism Hormones: The drugs mechanism of action involves activating three hormones: GLP-1, GIP, and glucagon
If you are in Tucson, Phoenix, or elsewhere in Arizona, review our medical weight loss program or Phoenix medical weight loss guide
